154 related articles for article (PubMed ID: 31237218)
1. Proteomics Screening of Differentially Expressed Cytokines in Tears of Patients with Graves' Ophthalmopathy.
Song RH; Wang B; Yao QM; Li Q; Jia X; Zhang JA
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):87-95. PubMed ID: 31237218
[TBL] [Abstract][Full Text] [Related]
2. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines.
Ujhelyi B; Gogolak P; Erdei A; Nagy V; Balazs E; Rajnavolgyi E; Berta A; Nagy EV
Thyroid; 2012 Apr; 22(4):407-14. PubMed ID: 22385289
[TBL] [Abstract][Full Text] [Related]
3. The tear cytokine profile in patients with active Graves' orbitopathy.
Yang M; Chung Y; Lang S; Yawata N; Seah LL; Looi A
Endocrine; 2018 Feb; 59(2):402-409. PubMed ID: 29147850
[TBL] [Abstract][Full Text] [Related]
4. Tear-derived exosomal biomarkers of Graves' ophthalmopathy.
Shi TT; Zhao RX; Xin Z; Hou ZJ; Wang H; Xie RR; Li DM; Yang JK
Front Immunol; 2022; 13():1088606. PubMed ID: 36561758
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 expression in tears and orbital tissues of patients with Graves' ophthalmopathy.
Cai K; Wei R
Endocrine; 2013 Aug; 44(1):140-4. PubMed ID: 23188693
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.
van Steensel L; Paridaens D; Dingjan GM; van Daele PL; van Hagen PM; Kuijpers RW; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1002-7. PubMed ID: 19797221
[TBL] [Abstract][Full Text] [Related]
7. The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.
Khazaei H; Khazaei D; Verma R; Ng J; Wilmarth PA; David LL; Rosenbaum JT
Exp Eye Res; 2021 Dec; 213():108813. PubMed ID: 34742692
[TBL] [Abstract][Full Text] [Related]
8. Microarray Data of Lacrimal Gland Implicates Dysregulated Protein Processing in Endoplasmic Reticulum in Graves' Ophthalmopathy.
Tu W; Yao J; Mei Z; Jiang X; Shi Y
Front Endocrinol (Lausanne); 2020; 11():571151. PubMed ID: 33613444
[TBL] [Abstract][Full Text] [Related]
9. The expression of intercellular adhesion molecule-1 induced by CD40-CD40L ligand signaling in orbital fibroblasts in patients with Graves' ophthalmopathy.
Zhao LQ; Wei RL; Cheng JW; Cai JP; Li Y
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4652-60. PubMed ID: 20107176
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
Clin Endocrinol (Oxf); 2016 Nov; 85(5):805-812. PubMed ID: 27256639
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Graves' ophthalmopathy patients' tear protein spectrum.
Jiang LH; Wei RL
Chin Med J (Engl); 2013 Dec; 126(23):4493-8. PubMed ID: 24286413
[TBL] [Abstract][Full Text] [Related]
12. The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients.
Chen Q
J Cell Biochem; 2019 Apr; 120(4):6299-6303. PubMed ID: 30565709
[TBL] [Abstract][Full Text] [Related]
13. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
14. Association of PARP-1, NF-κB, NF-κBIA and IL-6, IL-1β and TNF-α with Graves Disease and Graves Ophthalmopathy.
Niyazoglu M; Baykara O; Koc A; Aydoğdu P; Onaran I; Dellal FD; Tasan E; Sultuybek GK
Gene; 2014 Sep; 547(2):226-32. PubMed ID: 24956560
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.
Choi W; Li Y; Ji YS; Yoon KC
BMC Ophthalmol; 2018 Nov; 18(1):303. PubMed ID: 30463536
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy.
Huang D; Xu N; Song Y; Wang P; Yang H
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):619-25. PubMed ID: 22124787
[TBL] [Abstract][Full Text] [Related]
18. Gene expression in Graves' ophthalmopathy and arm lymphedema: similarities and differences.
Planck T; Parikh H; Brorson H; Mårtensson T; Åsman P; Groop L; Hallengren B; Lantz M
Thyroid; 2011 Jun; 21(6):663-74. PubMed ID: 21510802
[TBL] [Abstract][Full Text] [Related]
19. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy.
Huang D; Luo Q; Yang H; Mao Y
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4935-43. PubMed ID: 24994866
[TBL] [Abstract][Full Text] [Related]
20. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
